Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.

INTRODUCTION: Dolutegravir/rilpivirine (DTG/RPV) is an effective antiretroviral (ART) regimen endorsed by clinical trials as a switch therapy. The aim of our study was to analyse the efficacy and safety of DTG/RPV in real-world clinical practice. METHODS: Observational, multicentre study of patients who started DTG/RPV. Efficacy, adverse events and metabolic changes at 48 weeks were analysed. RESULTS: A total of 348 patients were included; median time of HIV infection was 21.1 years, 33.7% were AIDS cases; median nadir CD4 was 160 cells/µL; 90.5% had received ≥3 lines of ART and 179 (53.8%) had prior virological failure. Convenience (43.5%), toxicity/intolerance (28.4%) and interactions (17.0%) were the main reasons for starting DTG/RPV. Previous regimens were protease inhibitors (PI) (31.6%), non-nucleoside reverse transcriptase inhibitors (NNRTI) (20.4%) and integrase strand transfer inhibitors (INSTI) (14.9%). Efficacy (HIV-RNA <50 copies/mL) at 48 weeks was 89.7% (95% CI 86.1-92.6) by intention-to-treat (ITT) and 94.2% (95% CI 91.3-96.4) by on treatment (OT); 10 patients (3.1%) were not suppressed (3 had abandoned ART). There was a mean decrease in triglycerides, total cholesterol, low-density lipoprotein-cholesterol, glutamic-pyruvic transaminase (GPT), gamma-glutamyl transferase (GGT) and alkaline phosphatase; creatinine increased with a decrease in glomerular filtration rate. CONCLUSIONS: This study confirms the effectiveness, tolerability and safety of DTG/RPV in real-world clinical practice in a different population from clinical trials, with many years of infection, low CD4 nadir, several previous treatment lines, more than half with virological failures, and one-third diagnosed with AIDS. The switch to DTG/RPV was safe with few discontinuations due to adverse effects. Modifications of the lipid and liver profiles were favourable. There were no relevant changes in kidney function.

[Tumour form of neurocysticercosis in a patient with prostate carcinoma]. / Forma tumoral de neurocisticercosis en un paciente con carcinoma de próstata.

INTRODUCTION: Neurocysticercosis is a parasitic infection of the central nervous system caused by contact with the eggs of the parasite Taenia solium, which subsequently lodge in brain and eye tissue. It manifests itself in the form of cystic lesions scattered throughout the brain parenchyma that are usually small in size and, depending on their stage of development, may appear with associated oedema or with calcifications inside them. CASE REPORT: We report the case of a 63-year-old male visiting due to constitutional symptoms, generalised pain and confusion. A cranial computed axial tomography (CAT) scan showed a right frontoparietal lesion with a cyst-like appearance and surrounding oedema, as well as several smaller lesions with calcifications inside them. Given the pseudotumoural appearance, an extension study was performed and a prostatic adenocarcinoma with universal bone metastases was detected. Treatment with antiparasitic medication and dexamethasone was started, with a good initial response, which later worsened with the onset of left hemiparesis. In the follow-up CAT scan, an increase in the right frontoparietal lesion with increased oedema was observed, related to the inflammatory response to the treatment. After a new course of antiparasitic drugs, the patient maintained a sustained and stable clinical response. CONCLUSIONS: The unusual feature of this case was a rare presentation of neurocysticercosis in the form of a pseudotumoural lesion. Few cases have been reported in the literature, and it is important to maintain a high level of clinical and radiological suspicion, as this type of lesion may be more resistant to the penetration of antiparasitic drugs and require longer treatment and even surgery.

TITLE: Forma tumoral de neurocisticercosis en un paciente con carcinoma de próstata.Introducción. La neurocisticercosis es una infección parasitaria del sistema nervioso central que se produce por contacto con los huevos del parásito Taenia solium, que posteriormente se acantona en el tejido cerebral y ocular. Se manifiesta en forma de lesiones quísticas dispersas por el parénquima cerebral que suelen ser de pequeño tamaño y, dependiendo del estadio evolutivo en el que se presenten, pueden aparecer con edema asociado o con calcificaciones en su interior. Caso clínico. Varón de 63 años que consulta por cuadro constitucional, dolores generalizados y confusión. En la tomografía axial computarizada (TAC) craneal se visualiza una lesión frontoparietal derecha de 4 cm de diámetro, de aspecto quístico y edema circundante, así como varias lesiones de menor tamaño con calcificaciones en su interior. Dado el aspecto pseudotumoral, se realiza un estudio de extensión y se detecta un adenocarcinoma prostático con metástasis óseas universales. Se comienza un tratamiento con antiparasitarios y dexametasona con buena respuesta inicial, y empeora posteriormente con la aparición de una hemiparesia izquierda. En la TAC de control se observa un aumento de la lesión frontoparietal derecha con mayor edema, en relación con la respuesta inflamatoria con el tratamiento. Tras un nuevo ciclo de antiparasitarios, mantiene una respuesta clínica sostenida y estable. Conclusiones. Este caso tiene la peculiaridad de una forma de presentación poco frecuente de neurocisticercosis en forma de lesión pseudotumoral. Existen pocos casos descritos en la bibliografía, y es importante mantener un alto nivel de sospecha clínica y radiológica, ya que este tipo de lesiones puede ser más resistente a la penetración de antiparasitarios y precisar un tratamiento más prolongado e incluso quirúrgico.

Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain.

OBJECTIVES: Spain is close to HCV microelimination, so rates of recently acquired HCV infection (RAHC) should decrease. Nowadays, men who have sex with men (MSM) carry the highest risk of HCV acquisition. Our aim was to estimate the incidence of and the factors associated with RAHC, together with reinfection rates, among patients sexually infected by HIV. METHODS: Primary RAHC infection was diagnosed when anti-HCV antibody seroconversion was documented. In anti-HCV positive patients, initially without HCV viraemia, a diagnosis of reinfection was established if plasma HCV RNA was detected. RESULTS: All 350 patients tested negative for anti-HCV at baseline and had at least one follow-up visit. Among them, there were 16 RAHC cases from 2016 to 2019. RAHC incidence rates [IR (95% confidence interval, CI)] per 100 person-years were 3.77 (0.5-12.9) in 2016, 1.85 (0.6-4.3) in 2017, 1.49 (0.4-3.8) in 2018 and 1.98 (0.6-4.5) in 2019. Only previous sexually transmitted infections [incidence rate ratio (IRR) = 18.23, 95% CI: 1.93-172.1; P = 0.011], male sex (IRR = 8.33, 95% CI: 1.38-54.15; P = 0.026) and sharing chem-sex drugs (IRR: 4.93, 95% CI: 1.17-20.76; P = 0.030), were independently associated with RAHC. Four out of 42 (9.5%) patients became reinfected. CONCLUSIONS: The incidence of RAHC among HIV-infected patients showed a decrease after 2016, although a lower but steady incidence of residual cases still remains. HCV reinfections showed a similar pattern. New infections were associated with sharing chem-sex drugs among MSM.

Highlights in HIV, 2016.

Research in HIV-infection continues to grow every year. Reports published in journals or presented at conferences in 2016-2017 have brought light to some issues that had been highly debated. We have selected three conceptual publications, which we find include important information for clinicians taking care of HIV-infected patients.

[Multidrug-resistant tuberculosis: current epidemiology, therapeutic regimens, new drugs]. / Tuberculosis multirresistente: epidemiología actual, esquemas terapéuticos, nuevos fármacos.

Multidrug and extensively resistant tuberculosis are especially severe forms of the disease for which no efficacious therapy exists in many cases. All the countries in the world have registered cases, although most of them are diagnosed in resource-limited countries from Asia, Africa and South America. For adequate treatment, first- and second-line antituberculosis drugs have to be judiciously used, but the development of new drugs with full activity, good tolerability and little toxicity is urgently needed. There are some drugs in development, some of which are already available through expanded-access programs.